跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
JIVI
Authorized
STANDARD
JIVI
Bayer Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
59e90cd7b4f834d6
Company
Bayer Inc
Type
Standard
Approval Details
Approval Id
59e90cd7b4f834d6
Drug Approval Canada Name
JIVI
Product Name
JIVI
Status
Marketed
Status Date
2020-01-27
Original Market Date
2020-01-27
Din
02481790
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Schedule D
Ahfs
20:00.00
Atc Original
B02BD02 COAGULATION FACTOR VIII
Atc Name
b 02 bd 02
Aig Number
0160750005
Company Name
Bayer Inc
Company Address
2920 Matheson Blvd East, Mississauga, Ontario, Canada, L4W 5R6
Active Ingredients
ANTIHEMOPHILIC FACTOR (RECOMBINANT, B-DOMAIN DELETED, PEGYLATED)
3000 UNIT / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
59e90cd7b4f834d6
Type
Standard
Back to Health Canada Approvals
JIVI - Health Canada Drug Approval Details